Enliven Therapeutics
ELVN
125 hedge funds and large institutions have $961M invested in Enliven Therapeutics in 2025 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 45 reducing their positions, and 26 closing their positions.
4.85% more ownership
Funds ownership: 100.28% → 105.13% (+4.8%)
2% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 45
7% less funds holding
Funds holding: 134 → 125 (-9)
21% less capital invested
Capital invested by funds: $1.22B → $961M (-$255M)
27% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 26
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
73% less call options, than puts
Call options by funds: $203K | Put options by funds: $765K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$53.2M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$20.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.25M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$8.34M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$5.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DFO
Duquesne Family Office
New York
|
-$19.4M |
| 2 |
FTM
First Turn Management
Del Mar,
California
|
-$16M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$8.19M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$8.17M |
| 5 |
Blackstone Inc
New York
|
-$7.28M |
ELVN Hedge Fund Activity: Q4 2025 in Review
125 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q4 2025, worth a combined $961M — down 21% from $1.22B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ELVN and 19 opened new positions — a net loss of 7 holders — while 45 trimmed existing stakes and 46 added.
The largest buyer was Vestal Point Capital, adding an estimated $53.2M. The largest seller was Duquesne Family Office, exiting entirely with an estimated $19.4M sold.
- 125 institutional investors held Enliven Therapeutics (ELVN) as of Q4 2025, down from 134 in Q3 2025.
- Funds reported $961M of Enliven Therapeutics stock for Q4 2025, down 21% quarter-over-quarter.
- 19 funds opened new Enliven Therapeutics positions in Q4 2025 and 26 closed out, a net change of -7 holders.
- The largest Enliven Therapeutics buyer in Q4 2025 was Vestal Point Capital, an estimated $53.2M added.
- The largest Enliven Therapeutics seller in Q4 2025 was Duquesne Family Office, an estimated $19.4M sold.
Based on aggregated 13F filings for Q4 2025.